Device Trial Radar · NCT06264427
Phenotypic and Genotypic Characterization of Patients With Dysmetabolism in Greenland
Last checked: Nov 19, 2026Latest source record: Feb 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,000
Planned (sponsor's estimate)
Start
Jul 15, 2022
Primary completion
Dec 31, 2025
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Steno Diabetes Center GreenlandAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Zealand University Hospital; University of Copenhagen
- First posted
- Feb 20, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to perform a detailed description of the feno- and genotype of people living with type 2 diabetes and severe obesity who are linked to care at Steno Diabetes Center Greenland. The main questions it aims to answer are: * Are monogenetic diabetes variants associated with the same risk of developing late diabetic complications as other types of diabetes? * Can genotyping and thereby personalized medicine be implemented in Greenland, and can personalized medicine lead to improved treatment? * What is the prevalence of sleep apnea among high-risk individuals in Greenland? * Is it possible to develop and implement a simple algorithm for the identification of sleep apnea in Greenland that can ensure treatment of severe sleep apnea? Participants will: * Answer WHO-5 and FOSQ-10 questionnaires regarding quality of life and functional outcomes of sleepiness * Perform VAGUS examinations for Cardiovasculare Autonomic Neuropathy * Clinical examination of height, weight, circumference of hip, waist and neck, Friedman tonsil and tongue score, nasal air flow, nasal septal deviation * Blood samples for full genome sequencing
Conditions
- Diabetes Mellitus, Type 2
- Obesity, Morbid
- Obstructive Sleep Apnea
- MODY
- Diabetic Retinopathy
- Diabetic Neuropathies
Interventions
Whole genome sequencingGenetic
Screening for MODY diabetes. Diabetic treatment will be adjusted based on the participant's diabetic genotype.
VAGUSDiagnostic test
To examine for Cardiovasculare Autonomic Neuropathy participants will be tested with the handheld Vagus device (Medicus Engineering, Aarhus, Denmark). Participants are instructed to perform three cardiovascular reflex tests (CARTs) after lying still in supine position for 5 minutes to record heart rate at rest. CARTs include supine-to-upright position, deep-breathing, and valsalva maneuver. From each CART the ratio based on the shortest and longest R-R-interval at predefined timepoints in the recording is used to assess the possibility of CAN
NightOwlDiagnostic test
Participants will be examined for sleep apnea for 3 nights using the NightOwl (Ectosense, Belgium) device, which measuring Peripheral Arterial Tonometry (PAT) in the index finger. The results of the examination will is uploaded via the patient's smartphone to an online platform accessible to healthcare providers. Participants with signs of sleep apnea will receive a confirmatory cardiorespiratory monitoring using the Nox T3s (Noxturnal, ResMed), and the results will be compared.
CPAPDevice
Participants with an Apnea-Hypoapnea-Index above 30, or above 15 with symptoms of sleep apnea, will be offered treatment with continuous positive airway pressure (CPAP).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with MODY diabetes and their complication statusTime frame: Blood drawn at inclusion. Results for participants ready after approximately 6 months.
- Number of participants with diabetic complicationTime frame: Types and number of complications are available at inclusion. No follow-up screenings for complications are performed.
- Number of participants with obstructive sleep apneaTime frame: Home sleep testing is performed for 3 nights after inclusion. Confirmatory home sleep examinations performed one day after the initial sleep examination. In total, four days examinations time.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Steno Diabetes Center Greenland, Queen Ingrids Hospital
Nuuk, Sermersooq, Greenland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.